Cardinal Health (CAH) Q3 2025

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Earnings

Cardinal Health delivered a strong fiscal third quarter, posting non-GAAP diluted EPS of $2.35, beating the $2.15 consensus estimate by 9.36%, as profit growth across all five operating segments drove the outperformance. Revenue came in at $54.88 bil… Read more Cardinal Health delivered a strong fiscal third quarter, posting non-GAAP diluted EPS of $2.35, beating the $2.15 consensus estimate by 9.36%, as profit growth across all five operating segments drove the outperformance. Revenue came in at $54.88 billion, essentially flat year-over-year and slightly below the $55.31 billion consensus, though that headline figure obscures underlying momentum; excluding the previously communicated OptumRx customer contract expiration, revenue grew 19%. The primary engine was the Pharmaceutical and Specialty Solutions segment, where profit climbed 14% to $662.00 million, fueled by brand and specialty pharmaceutical volume, MSO platform contributions, and generics program performance. Operating cash flow swung sharply to $2.92 billion from negative $27.00 million a year ago, a dramatic improvement driven by working capital movements. Management raised its full-year fiscal 2025 non-GAAP EPS guidance to $8.05 to $8.15, and signaled double-digit non-GAAP EPS growth in fiscal 2026, even as the company acknowledged up to $300 million in potential tariff-related costs and has begun implementing mitigation measures including workforce reductions.